<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55003938"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<byline>
	<affiliation>European Medicines Agency<lb/> Evaluation of Medicines for Human Use<lb/></affiliation>
	</byline>

	<address>7 Westferry Circus, Canary Wharf, London, E14 4HB, UK<lb/></address>

	<phone>Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45<lb/> </phone>
	
	<email>E-mail: mail@emea.europa.eu</email>

	<ptr type="web">http://www.emea.europa.eu<lb/></ptr>

	<note type="copyright">Â© European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged.<lb/> </note><reference>Doc.Ref.: EMEA/174363/2008<lb/></reference>

	<note type="other">CHMP ASSESSMENT REPORT<lb/> FOR Pradaxa<lb/> International Nonproprietary Name:<lb/> dabigatran etexilate<lb/> Procedure No. EMEA/H/C/829<lb/> Assessment Report as adopted by the CHMP with<lb/> all information of a commercially confidential nature deleted.<lb/> 2/36<lb/> EMEA 2008<lb/></note>
	
	<note type="other">TABLE OF CONTENTS<lb/></note>

		</front>
	</text>
</tei>
